Summary | Recent changes in senior personnel in the pharmaceutical industry

Compiled around the New Year, but also the pharmaceutical industry's senior personnel changes more frequent period, the following is the United States pharmaceutical companies recently occurred in the recruitment, dismissal and retirement of the news summary.
1, Zimmer Biomet Zimmer Biomet hired a former Medtron executive to spine and oral businesses.
Vafa Jamali will take over from Zimmer as chief executive of the newly split company.
will be in charge of the restructuring of Zimmer Biomet, which hopes to spine and dental products by mid-2022.
to build a new corporate structure, Zimmer wants to focus the company's core competencies on joint replacement, sports medicine, trauma care and surgical products.
, Jamali served as senior vice president of Medtronic.
previously, he was President of Medtron's Respiratory Digestion and Information Division.
, Jamali also served as Chief Commercial Officer at Rockley Photonics, an integrated optical chip manufacturer focused on healthcare, wearables and machine vision applications.
Slaoui, director of The New Crown Vaccine Program in the U.S. at Centessa Pharmaceuticals, said last month that he was ready to "move on and get back to private life and business."
Slaoui's next move is to serve as chief scientific officer of Centeressa Pharmaceuticals, a merger of 10 biotech companies with an initial capital of $250 million.
Centessa's name is based on the words center (center) and asset, and co-founder Dr Francesco De Rubertis said: "Centessa's operations will be driven by an asset-centric approach, with each Centessa subsidiary focusing on the execution of its research and development product line and overseen by an experienced Centersa management team."
company's research and development program covers oncology, hematology, immunology, inflammatory diseases, neuroscience, and rare diseases.
3, Affinia Therapeutics Affinia has added two Novarca and Editas research and development backbones to the company.
Charles Albright, a former Editas researcher, will be Affinia's chief scientist, while Novarian's Dr. Petra Kaufmann will serve as Affinia's chief medical officer.
Albright will serve as chief scientific officer of gene therapy biotechnology Affinia Therapeutics, while Kaufmann will serve as chief medical officer.
at Novarma, Kaufmann led the clinical development of Zolgensma, a gene therapy for spinal muscular dystrophy.
Kaufmann, who has worked in academia and at the National Institutes of Health for a long time, has held several positions, including director of the Office of Rare Disease Research, before joining AveXis.
Albright previously led Editas' top scientists in gene editing technology.
, he spent more than a decade at Bristol Myers Squibb and became vice president of the company's genetic diseases and genomics division.
4, jCyte JCyte appointed Samir Mody Chief Commercial Officer, while Friedrich Asmus served as Senior Vice President of Clinical Development and Medical Affairs.
, the company also appointed Joel Centeno Senior Vice President of Manufacturing, Quality and Supply Chain.
, a former vice president of strategy, health economics and reimbursement at CRHF, is from Medtronic.
Asmus previously served as Vice President of Clinical Development at Ophthalmology Biotechnology ProQR Therapeutics, while Centeno worked at Boston Scientific, Hologic and AltheaDx.
5, Antios Therapeutics Antoios Therapeutics appointed Tamra Adams chief financial officer, the company's new executive role.
joining Antios, Adams founded Acting Concepts, which provides CFOs, accounting and financial services to emerging growth companies in the biopharmaceutical and information technology industries, including Engage Therapeutics.
6 and OncoSecOncoSec appointed Dr. Bridget O'Keeffe Vice President of Clinical Development on February 18.
, O'Keefe served as Senior Director of Clinical Development at Newtar Therapeutics.
, she held positions at Exelixis, Genentech, Clovis Oncology, Achaogen and Calitera.
7, Lyra Therapeutics signed with Robert Kern, M.D., as Chief Medical Officer.
will continue to serve as Professor and Chairman of George A. Sisson, Department of Head and Neck Surgery, Department of Otolaryngology, Feinberg School of Medicine, Northwestern University.
kearn joined Northwestern University more than 20 years ago and became dean of the Department of Otolaryngology in 2006.
8, Westlake Village BioPartners Westlake Village BioPartners appointed Peter Calveley chief operating officer.
12 years in investment banking and was managing director of SVB Leerink Investment Banking Group, responsible for companies in the biotechnology sector in the Western United States and Canada.
9, Cue Biopharma of Cue Biopharma, Cambridge, Massachusetts, appointed Matteo Levisetti, M.D., Senior Vice President of Clinical Development on February 22.
previously, Levisetti served as Chief Medical Officer at DNAtrix.
addition, he served as Chief Medical Officer at Dauntless Pharmaceuticals and at Big Pharmas Roche and Pfizer.
10, Avadel Pharmaceuticals Ireland Avadel Pharmaceuticals has appointed Richard Kim to a new position as Chief Commercial Officer.
, Kim will oversee the commercialization of the company's products in the United States.
joined Avadel, Kim worked at Intercept Pharmaceuticals as President of Business and Strategic Marketing in the United States.
11, Coherus BioSciences Coherus BioSciences appointed McDavid Stilwell chief financial officer.
Willwell will take over from the current chief financial officer, Dr Jean-Frédéric Viret, who will resign on March 7.
Stilwell joined Coherus in 2020, having previously served as Senior Vice President of Communications and Investor Relations at Sangamo Therapeutics.
12, Day One Biopharmaceuticals South San Francisco Day One Biopharmaceutical Company appointed Charles York II chief operating and financial officer, while her predecessor Natalie Holles joined the company's board of directors.
York resigned from Aeglea Bio Therapeutics, where he served as chief financial officer and head of enterprise development and has been a member of the leadership team since 2014.
source: Chutes and Ladders-Zimmer Biomet calls on Medtronic vet Jamali to lead spinout